公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2013 | Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept | Wang T.-S.; TSEN-FANG TSAI | Dermatologica Sinica | 12 | 13 | |
2020 | Safety and Effectiveness of Hyaluronic Acid Fillers With Lidocaine for Full-Face Treatment in Asian Patients | Huang, She-Hung; TSEN-FANG TSAI | Journal of drugs in dermatology : JDD | 3 | 3 | |
2018 | Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2 | Genovese M.C.; Combe B.; Kremer J.M.; TSEN-FANG TSAI ; Behrens F.; Adams D.H.; Lee C.; Kerr L.; Nash P. | Rheumatology (United Kingdom) | 35 | 33 | |
2020 | Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials | Puig L.; TSEN-FANG TSAI ; Bhutani T.; Uy J.; Ramachandran P.; Song M.; You Y.; Gooderham M.; Lebwohl M. | Journal of the European Academy of Dermatology and Venereology | 23 | 17 | |
2012 | The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection | TSEN-FANG TSAI ; Ho V.; Song M.; Szapary P.; Kato T.; Wasfi Y.; Li S.; Shen Y.K.; Leonardi C. | British Journal of Dermatology | 83 | 64 | |
2018 | Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentric prospective cohort study | HSIEN-YI CHIU ; Hui R.C.-Y.; Huang Y.-H.; Huang R.-Y.; Chen K.-L.; Tsai Y.-C.; Lai P.-J.; Wang T.-S.; TSEN-FANG TSAI | Acta Dermato-Venereologica | 56 | 45 | |
2013 | The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C | HSIEN-YI CHIU ; CHIEN-HUNG CHEN ; Wu M.-S.; Cheng Y.-P.; TSEN-FANG TSAI | British Journal of Dermatology | 121 | 101 | |
2000 | Sclerosing Perineurioma | TSEN-FANG TSAI | 中華皮膚科醫學雜誌 | 0 | 0 | |
2000 | Sebaceoma (Sebaceous Epithelioma) -A Case Report- | TSEN-FANG TSAI | 中華皮膚科醫學雜誌 | 0 | 0 | |
2001 | Sebaceous Trichofolliculoma -A Case Report- | TSEN-FANG TSAI | 中華皮膚科醫學雜誌 | 0 | 0 | |
2001 | Sebaceous Trichofolliculoma —A Case Report. | TSEN-FANG TSAI | Dermatol Sinica | | | |
2021 | Secukinumab 2-weekly vs. 4-weekly dosing in plaque-type psoriasis | TSEN-FANG TSAI | British Journal of Dermatology | 1 | 1 | |
2019 | Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study | Lee M.-G.; Huang Y.-H.; Lee J.-H.; Lee S.-C.; Kim T.-G.; Aw D.C.-W.; Bao W.; Dee C.M.A.; Guana A.; TSEN-FANG TSAI | Journal of Dermatology | 10 | 11 | |
2019 | Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study | Tha?i D.; Puig L.; Reich K.; TSEN-FANG TSAI ; Tyring S.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Lacombe A.; Xia S.; Bhosekar V.; Gilloteau I.; Guana A.; Blauvelt A. | Journal of the American Academy of Dermatology | 15 | 13 | |
2020 | Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment | TSEN-FANG TSAI | The British journal of dermatology | 2 | 2 | |
2014 | Secukinumab in plaque psoriasis - Results of two phase 3 trials | Langley R.G.; Elewski B.E.; Lebwohl M.; Reich K.; Griffiths C.E.M.; Papp K.; Puig L.; Nakagawa H.; Spelman L.; Sigurgeirsson B.; Rivas E.; TSEN-FANG TSAI ; Wasel N.; Tyring S.; Salko T.; Hampele I.; Notter M.; Karpov A.; Helou S.; Papavassilis C. | New England Journal of Medicine | 1599 | 1450 | |
2017 | Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience | Wang, Ting-Shun; CHIH-CHIEH CHAN ; HSIEN-YI CHIU ; TSEN-FANG TSAI | Dermatologica Sinica | 12 | 12 | |
2015 | Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial | Tha?i D.; Blauvelt A.; Reich K.; TSEN-FANG TSAI ; Vanaclocha F.; Kingo K.; Ziv M.; Pinter A.; Hugot S.; You R.; Milutinovic M. | Journal of the American Academy of Dermatology | 467 | 418 | |
2017 | Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1?year: Results from the CLEAR study | Blauvelt A.; Reich K.; TSEN-FANG TSAI ; Tyring S.; Vanaclocha F.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Hugot S.; You R.; Milutinovic M.; Tha?i D. | Journal of the American Academy of Dermatology | 254 | 227 | |
2023 | Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials | Langley, Richard G; Sofen, Howard; Dei-Cas, Ignacio; Reich, Kristian; Sigurgeirsson, Bardur; Warren, Richard B; Paul, Carle; Szepietowski, Jacek C; TSEN-FANG TSAI ; Hampele, Isabelle; You, Ruquan; Charef, Pascal; Papavassilis, Charis | The British journal of dermatology | 6 | | |